HighTower Advisors’s IGC Pharma IGC Stock Holding History

HighTower Advisors’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.63K	Buy	+10,000	New	+$2.77K	﹤0.01%	3796

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HighTower Advisors's IGC Position: Q1 2026 in Review

HighTower Advisors opened a new position in IGC Pharma (IGC) in Q1 2026: 10,000 shares worth $2.63K. The stake represents ﹤0.01% of the portfolio and ranks #3796 among its holdings.

35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

HighTower Advisors held 10,000 shares of IGC Pharma worth $2.63K as of Q1 2026.
IGC Pharma was a new HighTower Advisors position in Q1 2026.
IGC Pharma made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3796 holding.
35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.